Conceptually, aberrant expression of a Rac-GEF in cancer cells could redirect receptor-mediated signaling toward strengthening Rac1 activation and cell motility, as established for example for the ErbB-receptor activated Rac-GEF P-Rex1 in luminal breast cancer (Sosa et al., 2010). The gene discussed is AKT1; the disease is cancer.